Physician profile
Payam Shakouri
NPI 1184963746
$929,880.66
in general payments reported to CMS, 2019-2025
35 companies · $125K in 2025
The $125K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94K · 2020: $45K · 2021: $127K · 2022: $193K · 2023: $171K · 2024: $175K · 2025: $125K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $235K · Honoraria: $107K · Travel and Lodging: $91K · Food and Beverage: $19K · Consulting Fee: $13K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,800 · Education: $623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $235,024.50 |
| Honoraria | $107,021.50 |
| Travel and Lodging | $91,173.12 |
| Food and Beverage | $19,490.84 |
| Consulting Fee | $13,400.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,800.00 |
| Education | $623.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $476,094.30 | 2019-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $144,154.04 | 2021-2025 | |
| Amgen INC. | $131,906.74 | 2019-2025 | Krystexxa, Tavneos, Repatha |
| Aurinia Pharma U.S., INC. | $52,492.42 | 2021-2025 | Lupkynis |
| Ani Pharmaceuticals, INC. | $50,913.40 | 2022-2025 | Purified Cortrophin Gel |
| Travere Therapeutics, INC. | $48,004.41 | 2023-2025 | Filspari |
| Astrazeneca Pharmaceuticals Lp | $9,906.18 | 2019-2025 | Farxiga, Lokelma, Flumist Quadrivalent |
| Vifor Pharma, INC. | $8,674.69 | 2019-2025 | Veltassa |
| Glaxosmithkline, LLC. | $1,906.92 | 2021-2024 | Benlysta, Jesduvroq |
| Mallinckrodt Hospital Products INC. | $1,288.94 | 2020-2025 | Acthar, Terlivaz |
| Opko Pharmaceuticals, LLC | $550.06 | 2019-2025 | Rayaldee |
| Calliditas Therapeutics US INC. | $519.75 | 2022-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $442.56 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Alexion Pharmaceuticals, INC. | $435.68 | 2019-2025 | Ultomiris |
| Novo Nordisk INC | $377.08 | 2019-2025 | Ozempic, Rybelsus |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $353.51 | 2021-2025 | Jardiance, Tradjenta |
| Novartis Pharmaceuticals Corporation | $352.31 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $349.73 | 2019-2025 | Jynarque, Voyxact |
| Mallinckrodt Enterprises LLC | $186.30 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $165.36 | 2020-2025 | Livtencity, Gattex |
| Lilly USA, LLC | $163.41 | 2019-2025 | Jardiance, Zepbound |
| Alnylam Pharmaceuticals INC. | $114.62 | 2022-2024 | Givlaari |
| Akebia Therapeutics INC | $110.50 | 2019-2024 | Vafseo, Auryxia |
| Nxstage Medical, INC. | $106.08 | 2024 | |
| Kyowa Kirin, INC. | $92.39 | 2024 | Crysvita |
| Genzyme Corporation | $35.59 | 2019-2020 | |
| Abbott Laboratories | $29.61 | 2021-2022 | |
| Ardelyx, INC. | $24.15 | 2025 | Ibsrela |
| Ucb, INC. | $23.90 | 2025 | Rystiggo |
| Apellis Pharmaceuticals, INC. | $21.70 | 2025 | |
| Janssen Pharmaceuticals, INC | $20.00 | 2019 | |
| Esperion Therapeutics, INC. | $19.71 | 2020 | |
| Shire North American Group INC | $17.80 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.29 | 2021 | |
| Allergan, INC. | $12.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Payam Shakouri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.